---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-011936"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2025-05-21T23:59:59+00:00"
generated_at: "2026-05-20T22:47:53.044038+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# MIRA Pharmaceuticals appoints Alan Weichselbaum as CFO; prior CFO Michelle Yanez resigns

## Summary
- CFO Michelle Yanez resigned effective May 16, 2025; mutual separation not based on any disagreement.
- Alan Weichselbaum appointed CFO effective May 15, 2025; also CFO of Telomir Pharma and CEO of The Wexus Group.
- Employment agreement: $60,000 annual salary (part-time, 20 hrs/week), 75,000 stock options vesting over 12 months.
- Weichselbaum brings over 30 years of corporate finance experience; previously at Philip Morris and Price Waterhouse.

## SEC filing metadata
- accession: 0001641172-25-011936
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2025-05-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 5.02, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000164117225011936/0001641172-25-011936-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000164117225011936/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-011936
- JSON: https://secwatch.observer/filing/0001641172-25-011936.json
- Plain text: https://secwatch.observer/filing/0001641172-25-011936.txt

## Key facts
- Executive change
  Alan Weichselbaum was appointed as Chief Financial Officer at MIRA PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: Effective May 15, 2025, the Company appointed Alan Weichselbaum as the Chief Financial Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1904286/000164117225011936/0001641172-25-011936-index.htm
- Executive change
  Michelle Yanez resigned as Chief Financial Officer at MIRA PHARMACEUTICALS, INC..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: Effective May 16, 2025, Michelle Yanez and the Company mutually agreed to release Ms. Yanez from her position as Chief Financial Officer, Treasurer and Secretary of MIRA Pharmaceuticals, Inc. (the “Company”), effective on that date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1904286/000164117225011936/0001641172-25-011936-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.